Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | TYMP | P19971 | 8/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.33 |
| ▸ | POLA1 | P09884 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12765886 | 0.95 | KDM4E (0.48) | KDM4ETYMPTAS1R3TAS1R1POLA1 | |
| SCHEMBL7197818 | 0.95 | KDM4E (0.48) | KDM4ETYMPTAS1R3TAS1R1POLA1 | |
| SCHEMBL21901666 | 0.93 | KDM4E (0.48) | KDM4ETYMPTAS1R3TAS1R1POLA1 | |
| SCHEMBL24115430 | 0.92 | KDM4E (0.46) | KDM4ETYMPTAS1R3TAS1R1POLA1 | |
| SCHEMBL7999585 | 0.92 | KDM4E (0.46) | KDM4ETYMPTAS1R3TAS1R1POLA1 | |
| SCHEMBL13255852 | 0.92 | KDM4E (0.46) | KDM4ETYMPTAS1R3TAS1R1POLA1 | |
| SCHEMBL10533862 | 0.89 | KDM4E (0.41) | KDM4ETYMP | |
| SCHEMBL17911715 | 0.88 | KDM4E (0.40) | KDM4ETYMPTAS1R3TAS1R1POLA1 | |
| SCHEMBL21902463 | 0.88 | KDM4E (0.43) | KDM4ETYMPTAS1R3TAS1R1POLA1 | |
| SCHEMBL7202323 | 0.88 | KDM4E (0.49) | KDM4ETYMPTAS1R3TAS1R1POLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220096649-A1 | IMMUNOMODULATING POLYNUCLEOTIDE CONJUGATES AND METHODS OF USE | HORIZON TECHNOLOGY FINANCE CORPORATION | 2022-03-31 | — | — | US | disclosed |
| US-20220056069-A1 | IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE | HORIZON TECHNOLOGY FINANCE CORPORATION | 2022-02-24 | — | — | US | disclosed |
| US-11203611-B2 | Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use | TOLLNINE, INC. (US) | 2021-12-21 | — | — | US | disclosed |
| WO-2020081744-A1 | IMMUNOMODULATING POLYNUCLEOTIDE CONJUGATES AND METHODS OF USE | TOLLNINE, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220056069-A1 | IMMUNOMODULATING POLYNUCLEOTIDES, ANTIBODY CONJUGATES THEREOF, AND METHODS OF THEIR USE | TYMP, DUT, PAICS | KDM4E 3872/4885TYMP 1/4885TAS1R3 4849/4885 |
| US-11203611-B2 | Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use | TYMP, DUT, PAICS | KDM4E 3872/4885TYMP 1/4885TAS1R3 4849/4885 |
| US-20220096649-A1 | IMMUNOMODULATING POLYNUCLEOTIDE CONJUGATES AND METHODS OF USE | PBK, CD47, NCL | KDM4E 3212/4885TYMP 33/4885TAS1R3 4747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.